Sionna Therapeutics is trading 5% lower at $5.71 after opening-market weakness on September 23, 2026, amid broader risk-off pressure on equities.
- The Nasdaq Composite is down 0.95%, while biotech is advancing, making sector weakness an unlikely explanation.
- Investors may also still be reassessing Sionna’s September 14 disclosure of disappointing cystic-fibrosis trial results, a 46% workforce reduction, and a shift toward a new dual-drug Phase 2a strategy.